Beam Therapeutics Inc. (BEAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
BEAM POWR Grades
- Quality is the dimension where BEAM ranks best; there it ranks ahead of 35.31% of US stocks.
- BEAM's strongest trending metric is Stability; it's been moving up over the last 177 days.
- BEAM's current lowest rank is in the Stability metric (where it is better than 2.7% of US stocks).
BEAM Stock Summary
- Of note is the ratio of BEAM THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; just 8.51% of US stocks have a lower such ratio.
- With a price/sales ratio of 37.39, BEAM THERAPEUTICS INC has a higher such ratio than 95.58% of stocks in our set.
- Revenue growth over the past 12 months for BEAM THERAPEUTICS INC comes in at 11,673.62%, a number that bests 99.76% of the US stocks we're tracking.
- Stocks that are quantitatively similar to BEAM, based on their financial statements, market capitalization, and price volatility, are RPTX, LYRA, KROS, INMB, and VACC.
- Visit BEAM's SEC page to see the company's official filings. To visit the company's web site, go to www.beamtx.com.
BEAM Valuation Summary
- In comparison to the median Healthcare stock, BEAM's price/earnings ratio is 142.53% lower, now standing at -9.4.
- BEAM's price/sales ratio has moved NA NA over the prior 36 months.
Below are key valuation metrics over time for BEAM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BEAM | 2023-01-30 | 32.3 | 4.2 | -9.4 | -9.5 |
| BEAM | 2023-01-27 | 34.7 | 4.5 | -10.1 | -10.2 |
| BEAM | 2023-01-26 | 33.6 | 4.3 | -9.8 | -9.9 |
| BEAM | 2023-01-25 | 34.1 | 4.4 | -9.9 | -10.0 |
| BEAM | 2023-01-24 | 34.1 | 4.4 | -10.0 | -10.1 |
| BEAM | 2023-01-23 | 34.0 | 4.4 | -9.9 | -10.0 |
BEAM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BEAM has a Quality Grade of D, ranking ahead of 6.52% of graded US stocks.
- BEAM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BEAM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | 1 | -0.966 |
| 2021-03-31 | 0 | 1 | -1.254 |
| 2020-12-31 | 0 | 1 | -1.054 |
| 2020-09-30 | 0 | 1 | -0.896 |
| 2019-12-31 | 0 | 1 | -1.360 |
BEAM Price Target
For more insight on analysts targets of BEAM, see our BEAM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $123.57 | Average Broker Recommendation | 1.36 (Strong Buy) |
BEAM Stock Price Chart Interactive Chart >
BEAM Price/Volume Stats
| Current price | $47.91 | 52-week high | $80.00 |
| Prev. close | $48.45 | 52-week low | $27.77 |
| Day low | $46.79 | Volume | 952,500 |
| Day high | $48.38 | Avg. volume | 836,604 |
| 50-day MA | $43.09 | Dividend yield | N/A |
| 200-day MA | $46.55 | Market Cap | 3.38B |
Beam Therapeutics Inc. (BEAM) Company Bio
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.
Latest BEAM News From Around the Web
Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
EDIT stock, BEAM stock win bullish views in Cantor gene editing coverage (NASDAQ:EDIT)Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM) were among biotechs to win Overweight ratings at Cantor Fitzgerald which launched gene editing coverage. |
Cathie Wood pours millions into these 2 stocks — this is what makes them attractive buysJanuary has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11% into the green, in what amounted to its best start to a year since 2001. That signals the appetite for risk is on again and that will be good news for Cathie Wood, the ARK Investment CEO, whose investing style heavily favors disruptors - equities that are naturally positioned at the risky end of the sca |
7 CRISPR Stocks With the Best Long-Term PotentialCRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. |
7 CRISPR Stocks With the Best Long-Term PotentialCRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks rise dramatically since going public. This can be attributed to the potential for CRISPR-based therapies to treat a wide range of genetic disorders and diseases, including cancer, sickle cell anemia, and cystic fibrosis. This technology also has potential applications for editing genes in animals... |
Shareholders in Beam Therapeutics (NASDAQ:BEAM) are in the red if they invested a year agoBeam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders should be happy to see the share price up 16% in the last month... |
BEAM Price Returns
| 1-mo | 18.65% |
| 3-mo | 26.48% |
| 6-mo | -27.51% |
| 1-year | -24.12% |
| 3-year | 132.35% |
| 5-year | N/A |
| YTD | 22.50% |
| 2022 | -50.92% |
| 2021 | -2.39% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...